Literatur: Vorhofflimmern, -flattern und Antikoagulation

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

  • 1. Vorhofflimmern - Gesichertes und Neues, Trappe, Ärzteblatt 1/2012, S. 1-7 [PDF-Version]
  • 2. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur Heart J 2010; 31: 967-975 [Pubmed 19176537]
  • 3. Rizos T, Wagner A, Jenetzky E, et al. Paroxysmal atrial fibrillation is more prevalent than persistent atrical fibrillation in acute stroke and transient ischemic attack patients. Cerebrovasc Dis 2011; 32: 276-282 [Pubmed 21893980]
  • 4. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867 [Pubmed 17577005]
  • 5. Wasmer K, Eckhardt L. Management of atrial fibrillation around the world: a comparison of current ACCF/AHA/HRS, CCS, and ESC guidelines. Europace 2011; 13: 1368-1374 [Pubmed 21712281]
  • 6. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GYH. Underuse of oral anticoagulants in atrial fibrillation: a systemic review. Am j med 2010; 123: 638-645. e634 [Pubmed 20609686]
  • 7. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429 [Pubmed 20802247]
  • 8. Kirchhof P, Näbauer M, Gerth A, et al. Impact of the type of centre on management of AF patients: surprising evidence for diffrences in antithrombotic therapy decisions. Thromb Haemost 2011; 105: [Pubmed 21544322]
  • 9. Meinerz T, Kirch W, Rosin L, et al. Management of atrial fibrillation by primary care physicans in Germany: baseline results of the ATRIUM registry. Clin Res Cardiol 2011; 100: 897-905 [Pubmed 21533828]
  • 10. Nieuwlaat R, Capucci A, Camm Aj, et al. Atrial fibrillation management: a prospectivesurvey in ESC member countries. Eur Heart J 2005; 26: 2422-2434 [Pubmed 16204266]
  • 11. Lane DA, Lip GY. Barriers to anticoagulation in patients with atrial fibrillation: changing physican-related factors. Stroke 2008; 39: 7-9 [Pubmed 18048849]
  • 12. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline). A report of the American College of Cardiology foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 123: 104-23 [Pubmed 21173346]
  • 13. Roy D, Talajic M, Nattel S, et al. for the Atrial Fibrillation and congestive Heart Failure Investigators: Rythm control versus rate control for atrial fibrillation and heart failure. N engl J Med 2008; 358. 2667-77 [Pubmed 18565859]
  • 14. Conolly SJ, Ezekowitz MD, Yusuf S, Eikeboom J, Oldgren P, Parekh A, et al.: Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51 [Pubmed 19717844]
  • 15. Jeff S. Healey, M.D., Stuart J. Connolly, M.D., Michael R. Gold, M.D., et al. Subclinical Atrial fibrillation and the Risk of Stroke. N Engl J Med 2012; 366:120-9 [NEJM 1105575]
  • 16. Rupert Bauersachs, Sebastian M. Schellong, sylvia Haas, Ulrich Tebbe, Horst-Eberhard Gerlach, Claudia Abletshauser, Christian Sieder, Nima Melzer, Peter Bramlage, Hanno Ries. CERTIFY*: Prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thrombosis and Haemostasis 2011; 105:981-988 [Pubmed 21505722]
  • 17. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008; 39:1901. [Pubmed 18420954]
  • 18. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012. [Pubmed 22246443]
  • 19. Fang MC, Go AS, Chang Y, et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51:810. [Pubmed 18294564]
  • 20. Ogilvie IM, Welner SA, Cowell W, Lip GY. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients. Thromb Haemost 2011; 106:34. [Pubmed 21614409]
  • 21. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139. [Pubmed 19717844]
  • 22. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883. [Pubmed 21830957]
  • 23. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981. [PubMed 1107039]
  • 24. European Heart Rhythm Association, European Association for Cardio-Thoracic Surgery, Camm AJ, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31:2369. [PubMed 20802247]
  • 25. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke 2009; 40:1410. [PubMed 19182090]
  • 26. Mant J, Hobbs FD, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 2007; 370:493. [PubMed 17693178]
  • 27. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med 2009; 151:297. [PubMed 19721017]
  • 28. Hart RG, Pearce LA. Current status of stroke risk stratification in patients with atrial fibrillation. Stroke 2009; 40:2607. [PubMed 19461020]
  • 29. Agarwal S, Hachamovitch R, Menon V. Current Trial-Associated Outcomes With Warfarin in Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation: A Meta-analysis. Arch Intern Med 2012. [PubMed 22450212]
  • 30. Fang MC, Go AS, Chang Y, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120:700. [PubMed 17679129]
  • 31. Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 2009; 54:999. [PubMed 19729116]
  • 32. Hughes M, Lip GY, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM 2007; 100:599. [PubMed 17846060]
  • 33. Olesen JB, Lip GY, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. Thromb Haemost 2011; 106:739. [PubMed 21789337]
  • 34. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: a modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107:584. [PubMed 22186961]
  • 35. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:546S. [PubMed 18574273]
  • 36. Paciaroni M, Agnelli G, Micheli S, Caso V. Efficacy and safety of anticoagulant treatment in acute cardioembolic stroke: a meta-analysis of randomized controlled trials. Stroke 2007; 38:423. [Pubmed 17204681]
  • 37. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S. [Pubmed 22315271]
  • 38. Singer DE, Chang Y, Fang MC, et al. Should patient characteristics influence target anticoagulation intensity for stroke prevention in nonvalvular atrial fibrillation?: the ATRIA study. Circ Cardiovasc Qual Outcomes 2009; 2:297. [Pubmed 20031854]
  • 39. Hart RG, Aguilar MI. Anticoagulation in atrial fibrillation: selected controversies including optimal anticoagulation intensity, treatment of intracerebral hemorrhage. J Thromb Thrombolysis 2008; 25:26. [Pubmed 17906918]
  • 40. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med 2007; 167:239. [Pubmed 17296878]
  • 41. Connolly SJ, Pogue J, Eikelboom J, et al. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008; 118:2029. [Pubmed 18955670]
  • 42. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106:968. [Pubmed 21901239]
  • 43. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115:2689. [Pubmed 17515465]
  • 44. Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med 2011; 155:653. [Pubmed 22084331]
  • 45. Faxon DP, Eikelboom JW, Berger PB, et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106:572. [Pubmed 21785808]
  • 46. Huber K, Airaksinen KJ, Cuisset T, et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Thromb Haemost 2011; 106:569. [Pubmed 21909592]
  • 47. Glazer NL, Dublin S, Smith NL, et al. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med 2007; 167:246. [Pubmed 17296879]
  • 48. Gallagher AM, Rietbrock S, Plumb J, van Staa TP. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Thromb Haemost 2008; 6:1500. [Pubmed 18573187]
  • 49. Gorin L, Fauchier L, Nonin E, et al. Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 2011; 140:911. [Pubmed 21436246]
  • 50. Fang MC, Go AS, Chang Y, et al. Warfarin discontinuation after starting warfarin for atrial fibrillation. Circ Cardiovasc Qual Outcomes 2010; 3:624. [Pubmed 20959565]
  • 51. Sadanaga T, Sadanaga M, Ogawa S. Evidence that D-dimer levels predict subsequent thromboembolic and cardiovascular events in patients with atrial fibrillation during oral anticoagulant therapy. J Am Coll Cardiol 2010; 55:2225. [Pubmed 20466203]
  • 52. Roldán V, Marín F, Muiña B, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 2011; 57:2496. [Pubmed 21497043]
  • 53. Tang RB, Dong JZ, Liu XP, et al. Is CHA2DS2-VASc score a predictor of left atrial thrombus in patients with paroxysmal atrial fibrillation? Thromb Haemost 2011; 105:1107. [Pubmed 21544316]
  • 54. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. N Engl J Med 2010; 363:1875. [NEJM 1007378]
  • 55. Ezekowitz MD, Wallentin L, Connolly SJ, et al. Dabigatran and warfarin in vitamin K antagonist-naive and - experienced cohorts with atrial fibrillation. Circulation 2010; 122:2246. [Pubmed 21147728]
  • 56. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123:2363. [Pubmed 21576658]
  • 57. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation 2012; 125:669. [Pubmed 22215856]
  • 58. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med 2012; 172:397. [Pubmed 22231617]
  • 59. Gage BF. Can we rely on RE-LY? N Engl J Med 2009; 361:1200. [Pubmed 19717843]
  • 60. Pradaxa (dabigatran etexilate) US prescribing information (Accessed on November 16, 2011). [DailyMed]
  • 61. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365:981. [Pubmed 21870978]
  • 62. Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011; 124:1573. [Pubmed 21900088]
  • 63. ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006; 367:1903. [Pubmed 16765759]
  • 64. ACTIVE Investigators, Connolly SJ, Pogue J, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009; 360:2066. [Pubmed 19336502]
  • 65. Connolly SJ, Eikelboom JW, Ng J, et al. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155:579. [Pubmed 22041946]
  • 66. Flaker GC, Gruber M, Connolly SJ, et al. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. Am Heart J 2006; 152:967. [Pubmed 18420954]
  • 67. Israel CW, Grönefeld G, Ehrlich JR, et al. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J Am Coll Cardiol 2004; 43:47. [Pubmed 18420954]
  • 68. Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992; 327:94. [Pubmed 1603141]
  • 69. Lip GY. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 2008; 336:614. [Pubmed 18340078]
  • 70. Anderson, J, Adams, C, Antman, E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 [www.cardiosource.org] (Accessed on September 18, 2007).
  • 71. Rubboli A, Halperin JL, Airaksinen KE, et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40:428. [PubMed 2999026]
  • 72. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2011; 57:1330. [Pubmed 21324629]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun